NANOLOGICA’S CFO LEAVES THE COMPANY
1 June, 2026
No Comments
Nanologica's Chief Financial Officer Eva Osterman has decided to leave the company. Eva will remain in the Group until 31
Investor relations (EN)
This is Nanologica
Nanologica is a Swedish life science tools company that provides consumables to pharmaceutical manufacturers. With a foundation in materials science and nanotechnology, we have developed an expertise in chromatography. Our products are used to purify pharmaceuticals during production using a technique called preparative chromatography.
We operate in a global niche market that is growing as a result of an increased demand for drugs for treating diabetes and obesity. Our silica-based purification media for preparative chromatography, NLAB Saga®, has been especially developed for the purification of peptide drugs, such as insulin and GLP-1 analogues. Due to effective purification and a long lifetime for NLAB Saga®, it can increase productivity and reduce costs for pharmaceutical manufacturers.
Our mission is to increase access to cost-effective drugs through its purification products, and thereby enable more patients around the world access to life-saving treatments for diabetes and obesity.
Read more:
5 Reasons
to invest in Nanologica
By developing chromatography products that enable pharmaceutical manufacturers to streamline production and lower their production costs, Nanologica not only strives to create value for its shareholders, but also to contribute to more patients having access to adequate treatments.
Bulletin from the Annual General Meeting 2026 Nanologica AB (publ)
21 May, 2026
No Comments
Nanologica AB (publ) today May 21, 2026 held its Annual General Meeting in Stockholm, at which the following resolutions were
Interim Report Q1 2026 Nanologica AB (publ)
20 May, 2026
No Comments
FINANCIAL SUMMARY Net sales for the first quarter amounted to SEK 21,456 thousand (10,751). Operating profit for the quarter amounted
Interim Report Q1 2026 Nanologica AB (publ)
20 May, 2026
No Comments
FINANCIAL SUMMARY Net sales for the first quarter amounted to SEK 21,456 thousand (10,751). Operating profit for the quarter amounted
Delårsrapport Q1 2026 Nanologica AB (publ)
20 May, 2026
No Comments
FINANSIELL SAMMANFATTNING Nettoomsättningen för första kvartalet uppgick till 21 456 TSEK (10 751) Rörelseresultatet för kvartalet uppgick till 66 484
Nanologica AB (publ) Publishes Annual Report for 2025
24 April, 2026
No Comments
Nanologica AB's Annual Report for 2025 has now been published on the company's website. The Annual Report in Swedish, as
Annual Report 2024
After many years of working with various technologies and products, Nanologica has developed into a pure chromatography company with products for purification of pharmaceuticals during production, on a global market. Today we provide pharmaceutical manufacturers with products that needed to manufacture fast-growing GLP-1 analogues and insulin. With these products and our expertise in method and application development, we can streamline our customers’ workflows and reduce their costs. This makes us relevant in a market characterized by both increasing volumes and an increased focus on costs.
Presentation of Nanologica
Follow this link for more video presentations and CEO interviews.
Company presentation made by CEO Andreas Bhagwani in September 2025.
Investor Pitch Deck November 2024.
Please contact us at ir@nanologica.com for more information.
Subscribe to our news
For further information, please contact:
Johanna Westerberg
Director IR, Communications and Marketing
